載入...
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
Background Trifluridine, a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as it is rapidly degraded via thymidine phosphorylase. An oral combination tablet combines trifluridine with a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride. Thi...
Na minha lista:
| 發表在: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer US
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5352756/ https://ncbi.nlm.nih.gov/pubmed/28111727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0409-9 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|